254 related articles for article (PubMed ID: 31503397)
1. Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion.
Smith JJ; Chatila WK; Sanchez-Vega F; Datta J; Connell LC; Szeglin BC; Basunia A; Boucher TM; Hauser H; Wasserman I; Wu C; Cercek A; Hechtman JF; Madden C; Jarnagin WR; Garcia-Aguilar J; D'Angelica MI; Yaeger R; Schultz N; Kemeny NE
Cancer Med; 2019 Nov; 8(15):6538-6548. PubMed ID: 31503397
[TBL] [Abstract][Full Text] [Related]
2. Mutation Status of
Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662
[TBL] [Abstract][Full Text] [Related]
3. Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy.
Datta J; Narayan RR; Goldman DA; Chatila WK; Gonen M; Strong J; Balachandran VP; Drebin JA; Kingham TP; Jarnagin WR; Schultz N; Kemeny NE; D'Angelica MI
Ann Surg; 2022 Nov; 276(5):e474-e482. PubMed ID: 33214457
[TBL] [Abstract][Full Text] [Related]
4. Coaltered
Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients.
Gholami S; Kemeny NE; Boucher TM; Gönen M; Cercek A; Kingham TP; Balachandran V; Allen P; DeMatteo R; Drebin J; Jarnagin W; D'Angelica M
Ann Surg; 2020 Aug; 272(2):352-356. PubMed ID: 32675549
[TBL] [Abstract][Full Text] [Related]
7. Interactions of multiple gene alterations in colorectal liver metastases.
Kawaguchi Y; Velasco JD; Arvide EM; Wei SH; Vauthey JN
Chin Clin Oncol; 2019 Oct; 8(5):50. PubMed ID: 31500427
[TBL] [Abstract][Full Text] [Related]
8. Gene mutation and surgical technique: Suggestion or more?
Kawaguchi Y; Lillemoe HA; Vauthey JN
Surg Oncol; 2020 Jun; 33():210-215. PubMed ID: 31351766
[TBL] [Abstract][Full Text] [Related]
9. Genomic and prognostic heterogeneity among RAS/BRAF
Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
[TBL] [Abstract][Full Text] [Related]
10. Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy.
Narayan RR; Datta J; Goldman DA; Aveson VG; Walch HS; Sanchez-Vega F; Gönen M; Balachandran VP; Drebin JA; Jarnagin WR; Kingham TP; Wei AC; Schultz N; Kemeny NE; D'Angelica MI
Ann Surg Oncol; 2022 Nov; 29(12):7579-7588. PubMed ID: 35896920
[TBL] [Abstract][Full Text] [Related]
11. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
Mizuno T; Cloyd JM; Vicente D; Omichi K; Chun YS; Kopetz SE; Maru D; Conrad C; Tzeng CD; Wei SH; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2018 May; 44(5):684-692. PubMed ID: 29551247
[TBL] [Abstract][Full Text] [Related]
12. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
Ince WL; Jubb AM; Holden SN; Holmgren EB; Tobin P; Sridhar M; Hurwitz HI; Kabbinavar F; Novotny WF; Hillan KJ; Koeppen H
J Natl Cancer Inst; 2005 Jul; 97(13):981-9. PubMed ID: 15998951
[TBL] [Abstract][Full Text] [Related]
13. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
Frankel TL; Vakiani E; Nathan H; DeMatteo RP; Kingham TP; Allen PJ; Jarnagin WR; Kemeny NE; Solit DB; D'Angelica MI
Cancer; 2017 Feb; 123(4):568-575. PubMed ID: 27737491
[TBL] [Abstract][Full Text] [Related]
14. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A
Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732
[TBL] [Abstract][Full Text] [Related]
15. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.
Chun YS; Passot G; Yamashita S; Nusrat M; Katsonis P; Loree JM; Conrad C; Tzeng CD; Xiao L; Aloia TA; Eng C; Kopetz SE; Lichtarge O; Vauthey JN
Ann Surg; 2019 May; 269(5):917-923. PubMed ID: 28767562
[TBL] [Abstract][Full Text] [Related]
16. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
17. Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer.
Kawaguchi Y; Kopetz S; Kwong L; Xiao L; Morris JS; Tran Cao HS; Tzeng CD; Chun YS; Lee JE; Vauthey JN
J Am Coll Surg; 2021 Aug; 233(2):272-284.e13. PubMed ID: 34111531
[TBL] [Abstract][Full Text] [Related]
18. Genomic Stratification of Resectable Colorectal Liver Metastasis Patients and Implications for Adjuvant Therapy and Survival.
Ecker BL; Shin P; Saadat LV; Court CM; Balachandran VP; Chandwani R; Drebin JA; Jarnagin WR; Kingham TP; Soares KC; Vakiani E; Wei AC; Kemeny NE; Smith JJ; Gonen M; D'Angelica MI
Ann Surg; 2022 Feb; 275(2):371-381. PubMed ID: 34793355
[TBL] [Abstract][Full Text] [Related]
19. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
Lévi FA; Boige V; Hebbar M; Smith D; Lepère C; Focan C; Karaboué A; Guimbaud R; Carvalho C; Tumolo S; Innominato P; Ajavon Y; Truant S; Castaing D; De Baere T; Kunstlinger F; Bouchahda M; Afshar M; Rougier P; Adam R; Ducreux M;
Ann Oncol; 2016 Feb; 27(2):267-74. PubMed ID: 26578731
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
